Marked under-diagnosis of Lambert-Eaton myasthenic syndrome in small cell lung cancer: an analysis of real-world claims data
In a large real-world cohort of patients with lung cancer, LEMS is diagnosed far less frequently than would be expected and rarely by oncologists. Because LEMS may convey substantial morbidity and specific LEMS treatments are available, further efforts to understand and address this discrepancy are warranted.
Authors
- David J. Morrell (ORCID: https://orcid.org/0000-0001-8785-425X)
- David E. Gerber (ORCID: https://orcid.org/0000-0002-7812-6741)
- Regina Grebla
- Benjamin J. Drapkin (ORCID: https://orcid.org/0000-0002-4824-7243)
- Guy Shechter
Institutions
- University of Pittsburgh at Bradford (US)
- Systems Analytics (United States) (US)
- Southwestern Medical Center (US)
- Catalyst Pharmaceuticals (United States) (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-10-17
- DOI
- https://doi.org/10.3389/fonc.2025.1650373
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Cancer Prevention and Research Institute of Texas
- University of Texas Southwestern Medical Center
- National Institutes of Health